This comprehensive session focuses on simplifying type 2 diabetes management through practical insights on DPP-4 inhibitors, with a special emphasis on linagliptin and its role across the disease trajectory. The discussion covers patient selection, renal considerations, cardiovascular safety, long-term glycemic durability, and real-world positioning in diverse clinical scenarios. A clinically oriented update designed to support confident, individualized diabetes care in everyday practice.

Simplifying Diabetes Care in the Current Era

This panel discussion brings together key perspectives on the interplay between heart, metabolic, and renal health, highlighting how SGLT2 inhibitor and DPP-4 inhibitor combinations are reshaping outcomes in patients with diabetes and associated co-morbidities. The session focuses on real-world evidence, patient selection, cardio-renal protection, and practical treatment strategies to achieve comprehensive cardio-renal-metabolic benefits in routine clinical practice.

Hearts, Hormones & Kidneys: Revolutionizing Cardio-Renal-Metabolic Wins with SGLT2i DPP4i combinations

The Cardio-Renal-Metabolic (CRM) Grand Rounds, is a specialized medical conference focused on the latest advancements in managing cardio-renal-metabolic conditions. The event brings together renowned experts in nephrology, endocrinology, and cardiology to discuss cutting-edge research, innovative treatment strategies, and multidisciplinary approaches to patient care. Attendees will gain insights into the evolving landscape of cardio-renal-metabolic health and practical knowledge to enhance patient outcomes.

Cardio-Renal-Metabolic Grand Rounds - Special Room

Cardio-Renal-Metabolic Grand Rounds

Chairman – Nephrology & Kidney Transplant, Epitome Hospital, New Delhi 

Persistent hypertension despite treatment can often point towards underlying aldosterone-mediated mechanisms. This expert-led session will explore the role of aldosterone in difficult-to-control hypertension, approaches to identifying patients with aldosterone-driven disease, and evolving strategies for targeted management. The discussion will also examine the emerging role of Aldosterone Synthase Inhibitors (ASI) and their potential to address unmet needs in patients with persistently uncontrolled blood pressure. Featuring insights from Dr. Vijay Kher, Prof. Dr. David Wheeler, and Dr. A G Unnikrishnan, the session will focus on practical perspectives and the evolving evidence shaping the future of hypertension management.

Dr. Vijay Kher

5

2.5k

53.5k

4.8

Upcoming Sessions

Sessions Taken

900

4.8

1.5k

4.8

524

0

570

4.7